CRISPR-Cas12a-Based Diagnostics for Rapid Detection of African Swine Fever Virus in Field Samples

Introduction

African swine fever virus (ASFV) is a large, enveloped, double-stranded DNA virus belonging to the family Asfarviridae and the sole member of the genus Asfivirus [1]. It causes a highly contagious and often fatal hemorrhagic disease in domestic swine and wild boar, with mortality rates approaching 100% in susceptible populations. The virus is endemic in sub-Saharan Africa, Sardinia, and parts of Eastern Europe and Asia, and its continued spread threatens global swine production. Early and accurate detection is critical for implementing control measures, but conventional laboratory-based methods such as real-time quantitative PCR (qPCR) require expensive thermal cyclers, trained personnel, and centralized facilities that are often unavailable in low-resource field settings [1].

The CRISPR-Cas12a system has emerged as a transformative platform for nucleic acid detection because it combines the programmable sequence recognition of CRISPR RNA (crRNA) with the collateral, non-specific cleavage activity of the Cas12a nuclease. When Cas12a binds its target DNA via crRNA complementarity, it activates a robust trans-cleavage activity that cuts nearby single-stranded DNA (ssDNA) molecules [1]. This property can be harnessed for diagnostic signal generation by including a fluorophore-quencher ssDNA reporter or a labeled ssDNA linker in a lateral flow format. For ASFV detection, the assay typically incorporates an isothermal pre-amplification step, such as recombinase polymerase amplification (RPA), to increase target copy number before Cas12a recognition, thereby achieving sensitivity comparable to qPCR [1].

This article provides a detailed scientific overview of a CRISPR-Cas12a-based diagnostic assay for ASFV, focusing on assay design, biophysical mechanisms, analytical performance, and field validation. Emphasis is placed on the utility of such assays for point-of-care (POC) diagnosis in low-resource environments.

Assay Design and Biophysical Mechanism

Guide RNA Selection and Target Regions

The diagnostic specificity of the CRISPR-Cas12a assay is determined by the crRNA sequence. For ASFV, crRNAs are designed to target highly conserved genomic regions to ensure broad detection across genotypes. The most common targets are the B646L gene encoding the major capsid protein p72 and the EP402R gene encoding the CD2v protein, both of which are essential for viral structure and hemadsorption, respectively [1]. These genes exhibit high sequence conservation among ASFV isolates, minimizing the risk of false negatives due to genetic drift. In the reported one-pot CRISPR-Cas12a assay, crRNAs targeting the p72 gene were validated and showed no cross-reactivity with classical swine fever virus (CSFV) or other porcine pathogens [1].

Recombinase Polymerase Amplification (RPA) Pre-Amplification

Because the collateral cleavage activity of Cas12a alone is insufficient to detect low-copy-number nucleic acids, an isothermal amplification step is integrated upstream. RPA is ideally suited for field deployment because it operates at a constant temperature (37-42°C) and does not require thermal cycling. The RPA reaction uses recombinase proteins to form a filament with primers, which then invades double-stranded DNA at the target locus, allowing strand displacement and exponential amplification [1]. In the ASFV assay, RPA primers are designed to flank the crRNA target region within the p72 gene. The entire RPA step is completed in 20-30 minutes, yielding sufficient amplicon to trigger Cas12a activation.

Cas12a Collateral Cleavage and Signal Readout

After RPA, the amplicon is recognized by the Cas12a-crRNA ribonucleoprotein complex. Binding of the target DNA induces a conformational change that activates the nuclease domain of Cas12a. The activated enzyme then non-specifically cleaves ssDNA molecules present in the reaction. Two readout modalities are commonly employed:

• Fluorescent reporter: An ssDNA oligonucleotide labeled with a fluorophore (e.g., FAM) and a quencher (e.g., BHQ1) at opposite ends. Cleavage separates the fluorophore from the quencher, generating a fluorescence signal that can be measured with a portable fluorometer or a simple blue-light transilluminator [1].

• Lateral flow strip: An ssDNA linker that bridges a gold nanoparticle conjugate and a capture antibody is cleaved. In the absence of target, the intact linker forms a colored line at the test zone. In the presence of target, cleavage disrupts the linker, and signal appears only at the control zone. This format provides a visual readout requiring no instrumentation [1].

The one-pot format, where RPA and Cas12a reactions are combined in a single tube, simplifies workflow and reduces contamination risk. The combined reaction is incubated at 37-42°C for 30-60 minutes, and results are interpreted either by fluorescence detection or lateral flow strip dipstick [1].

Analytical Performance

Limit of Detection and Sensitivity

The analytical sensitivity of the CRISPR-Cas12a assay for ASFV has been determined using serial dilutions of synthetic DNA standards and quantified viral genomic DNA. In the one-pot assay, the limit of detection (LOD) was reported as 2 copies per microliter of input, which is within the range of conventional qPCR [1]. When using a lateral flow readout, the visual LOD was slightly higher (approximately 10 copies per microliter) due to the inherent sensitivity limitations of colorimetric detection. Regardless, the assay consistently detected ASFV DNA in samples with cycle threshold (Ct) values below 35, corresponding to moderate to high viral loads typically observed in acutely infected swine [1].

Specificity Against Related Viruses

Cross-reactivity testing is essential for any diagnostics intended for field use, where multiple pathogens may be present. The RPA-CRISPR assay was tested against CSFV, porcine reproductive and respiratory syndrome virus (PRRSV), porcine circovirus type 2 (PCV2), and swine influenza A virus (SIV) [1]. No false positive signals were observed, confirming the high specificity conferred by the crRNA and RPA primer sets. This is particularly important because CSFV causes a clinically similar hemorrhagic disease, and differential diagnosis is critical for outbreak management.

Validation in Field Samples

Sample Types and Processing

Field validation was performed using porcine blood samples and oral fluids collected from farms with suspected ASFV outbreaks [1]. Blood samples were subjected to DNA extraction using commercial kits, while oral fluids were concentrated by centrifugation or processed directly. The extracted DNA was then added to the one-pot RPA-CRISPR reaction. For comparison, all samples were also tested using a validated qPCR assay targeting the same p72 gene.

In a cohort of 50 field samples, the CRISPR-Cas12a assay demonstrated 100% positive predictive agreement and 96% negative predictive agreement with qPCR, with only two discordant results that were later resolved as low-positive samples near the LOD of both methods [1]. The total turnaround time from sample to result, including DNA extraction, was under one hour, compared to 2-3 hours for qPCR.

Comparison with qPCR and LAMP

Real-time qPCR remains the gold standard for ASFV detection due to its high sensitivity and quantitative capacity. However, it requires a thermocycler and stable electricity. Loop-mediated isothermal amplification (LAMP) is an alternative isothermal method but often suffers from non-specific amplification and complex primer design. In head-to-head comparisons, the CRISPR-Cas12a assay matched the sensitivity of qPCR for samples with Ct values up to 33, and outperformed LAMP in specificity (no false positives) [1]. Moreover, the CRISPR assay's dual readout (fluorescence or lateral flow) offers flexibility that LAMP cannot provide without additional probe steps.

The following table summarizes key performance characteristics:

Point-of-Care Applicability in Low-Resource Settings

The CRISPR-Cas12a assay is designed for deployment in settings where laboratory infrastructure is limited. The one-pot format requires only a heat block (or even body heat for the RPA step) and a disposable UV light or lateral flow strip. Reagents can be lyophilized to improve thermostability without cold chain logistics. Sample preparation can be simplified using rapid DNA extraction methods (e.g., alkaline lysis) that add only 5-10 minutes. Because the assay does not require expensive equipment, it can be performed in mobile veterinary units, on farms, or at border checkpoints. The visual lateral flow readout eliminates the need for any electronic device, making it suitable for use by personnel with basic training [1].

Integration with Existing Diagnostic Workflows

The CRISPR-Cas12a assay should be viewed as a complementary tool rather than a direct replacement for qPCR. In a surveillance program, samples that test positive by the rapid assay can be sent to a reference laboratory for confirmatory genotyping and genomic sequencing, such as using high-throughput sequencers for outbreak tracing. Conversely, negative results from qPCR in samples with very low viral load might be cross-checked using the more rapidly deployable CRISPR assay for emergency screening. The assay can also be incorporated into multiplex panels targeting multiple swine pathogens, though current implementations are single-plex.

For further reading on ASFV pathogenesis and epidemiology, see the existing article on African Swine Fever Virus. For comparisons with other molecular techniques, articles on CRISPR-Cas12a and Cas13a Platforms for Rapid Veterinary Viral Diagnostics and Recombinase Polymerase Amplification (RPA) for Field Detection of Rabies Virus in Saliva Samples provide relevant methodological context. The performance of the CRISPR assay can also be contextualized with the Nanotechnology in Rapid Viral Diagnostic Tests overview.

The following Mermaid diagram illustrates the complete workflow of the one-pot RPA-CRISPR-Cas12a assay:

flowchart TD
    A[Sample collection: blood or oral fluid], > B[Rapid DNA extraction\n(alkaline lysis or kit)]
    B, > C[One-pot reaction mix:\nRPA primers, Cas12a-crRNA,\nssDNA reporter, buffer]
    C, > D[Incubate at 37-42°C for 30-40 min]
    D, > E{Amplicon generated?}
    E, >|Yes| F[Cas12a collateral cleavage\nof ssDNA reporter]
    E, >|No| G[No signal]
    F, > H[Signal readout]
    H, > I[Option 1: Fluorescence\n(portable fluorometer)]
    H, > J[Option 2: Lateral flow strip\n(visual line)]
    I, > K[Result interpretation\nin < 60 min]
    J, > K

Challenges and Future Perspectives

Despite its promise, the CRISPR-Cas12a assay has limitations. The need for a DNA extraction step, even if rapid, adds hands-on time and cost. Direct detection from raw oral fluid or blood without purification would further simplify the workflow but currently leads to inhibition of RPA and Cas12a enzymes [1]. Additionally, the quantitative capability of the assay is limited; it is primarily a qualitative or semi-quantitative tool. For absolute quantification, digital PCR methods (see Digital Droplet PCR for Absolute Quantification of Feline Leukemia Virus Proviral Load) provide superior accuracy.

Future developments may include integration with microfluidic cartridges for fully automated sample-to-result processing, multiplexing for simultaneous detection of multiple swine viruses (e.g., CSFV, PRRSV), and the incorporation of internal amplification controls to monitor reaction efficiency.

Conclusion

The CRISPR-Cas12a-based diagnostic assay for ASFV represents a significant advance in rapid, field-deployable molecular diagnostics for veterinary medicine. By combining isothermal RPA amplification with the trans-cleavage activity of Cas12a, the assay achieves sensitivity and specificity comparable to qPCR while requiring minimal instrumentation and reducing turnaround time to under one hour. Validation in porcine blood and oral fluid samples confirms its suitability for point-of-care use in low-resource settings. As the global swine industry continues to face ASFV outbreaks, such assays will become indispensable tools for early detection, outbreak containment, and surveillance.

References

[1] Gao X, Dong X, Song H, et al. A one-pot CRISPR-Cas12a-based assay for rapid, on-site detection of African swine fever virus. International Journal of Biological Macromolecules. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40680952/ *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.